Burt A.  Adelman net worth and biography

Burt Adelman Biography and Net Worth

Director of Verve Therapeutics
Burt Adelman is a thought leader and expert in drug development with more than 25 years of experience in the biotech industry. He was most recently executive vice president and chief medical officer at Dyax Corp., where he led the development of lanadelumab (Takhzyro), approved by the FDA and EMA for the prophylactic treatment of hereditary angioedema. Dyax was acquired by Shire in 2016. Dr. Adelman began his career at Biogen where he had an unparalleled track record, having led the successful development of important biologic therapeutics including Angiomax®, Avonex®, Amevive® and Tysabri®. At Biogen, he served in various roles including vice president of regulatory affairs, executive vice president of R&D, and executive vice president of portfolio strategy. Dr. Adelman is a member of the board of directors of Catabasis, Sirona, Clear Creek Bio, and Syntimmune, until it was sold to Alexion in 2018. He is also special advisor at Novo Ventures (US) Inc. He graduated from Cornell University Medical College, served as House Officer and Medical Resident at the Peter Bent Brigham Hospital (now Brigham and Women’s Hospital) and Harvard Medical School, and completed his hematology fellowship at Brigham and Women’s Hospital (BWH). Dr. Adelman is a member of the Tufts Medical School Board of Overseers, an advisor to the Boston Biomedical Innovation Center at BWH, and a member of the investment committee of the Partners Innovation Fund (Mass General Hospital and BWH).

What is Burt A. Adelman's net worth?

The estimated net worth of Burt A. Adelman is at least $126,038.00 as of May 12th, 2022. Dr. Adelman owns 18,700 shares of Verve Therapeutics stock worth more than $126,038 as of April 17th. This net worth estimate does not reflect any other assets that Dr. Adelman may own. Additionally, Dr. Adelman receives a salary of $87,550.00 as Director at Verve Therapeutics. Learn More about Burt A. Adelman's net worth.

How old is Burt A. Adelman?

Dr. Adelman is currently 72 years old. There are 5 older executives and no younger executives at Verve Therapeutics. Learn More on Burt A. Adelman's age.

What is Burt A. Adelman's salary?

As the Director of Verve Therapeutics, Inc., Dr. Adelman earns $87,550.00 per year. There are 4 executives that earn more than Dr. Adelman. The highest earning executive at Verve Therapeutics is Dr. Sekar Kathiresan M.D., Co-Founder, CEO & Director, who commands a salary of $899,550.00 per year. Learn More on Burt A. Adelman's salary.

How do I contact Burt A. Adelman?

The corporate mailing address for Dr. Adelman and other Verve Therapeutics executives is , , . Verve Therapeutics can also be reached via phone at 617-603-0070 and via email at [email protected]. Learn More on Burt A. Adelman's contact information.

Has Burt A. Adelman been buying or selling shares of Verve Therapeutics?

Burt A. Adelman has not been actively trading shares of Verve Therapeutics in the last ninety days. Most recently, on Thursday, May 12th, Burt A. Adelman bought 10,000 shares of Verve Therapeutics stock. The stock was acquired at an average cost of $12.15 per share, with a total value of $121,500.00. Following the completion of the transaction, the director now directly owns 18,700 shares of the company's stock, valued at $227,205. Learn More on Burt A. Adelman's trading history.

Who are Verve Therapeutics' active insiders?

Verve Therapeutics' insider roster includes Burt Adelman (Director), Andrew Ashe (Insider), Andrew Bellinger (Insider), and Sekar Kathiresan (CEO). Learn More on Verve Therapeutics' active insiders.

Are insiders buying or selling shares of Verve Therapeutics?

In the last twelve months, insiders at the sold shares 2 times. They sold a total of 2,068 shares worth more than $18,818.66. The most recent insider tranaction occured on April, 2nd when insider Joan Nickerson sold 1,514 shares worth more than $12,475.36. Insiders at Verve Therapeutics own 21.4% of the company. Learn More about insider trades at Verve Therapeutics.

Information on this page was last updated on 4/2/2024.

Burt A. Adelman Insider Trading History at Verve Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/12/2022Buy10,000$12.15$121,500.0018,700View SEC Filing Icon  
3/15/2022Buy4,000$21.38$85,520.00View SEC Filing Icon  
12/2/2021Buy4,700$31.34$147,298.00View SEC Filing Icon  
See Full Table

Burt A. Adelman Buying and Selling Activity at Verve Therapeutics

This chart shows Burt A Adelman's buying and selling at Verve Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verve Therapeutics Company Overview

Verve Therapeutics logo
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $6.74
Low: $6.72
High: $7.27

50 Day Range

MA: $12.50
Low: $6.74
High: $17.96

2 Week Range

Now: $6.74
Low: $6.72
High: $21.42

Volume

1,148,512 shs

Average Volume

1,242,399 shs

Market Capitalization

$563.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7